Hcw Biologics, Inc. (HCWB)
NASDAQ:HCWB
Want to see HCWB full AI Analyst Report?
Top Page
HCW Biologics
(NASDAQ:HCWB)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▼(-37.34% Downside)
Action:Reiterated
Date:05/22/26
The score is held down primarily by weak financial quality—large operating losses and deeply negative free cash flow that imply continued reliance on external funding. Technicals are supportive due to strong price strength versus moving averages, but overbought signals increase reversal risk. Corporate events are mixed (helpful licensing cash and Nasdaq compliance, but ongoing financing/dilution pressures), while valuation is difficult to rely on given losses.
Positive Factors
High gross margin & revenue rebound
Sustained revenue rebound with ~97% gross margin indicates attractive unit economics on recognized revenue streams. For a clinical-stage biotech, high gross margins mean commercializable components or partnerships can scale efficiently, improving capital efficiency for ongoing R&D over the next several months.
Negative Factors
Deep negative operating and free cash flow
Persistent ~-$11.5M cash burn across operating and free cash flow signals structural funding needs. Continued negative cash generation limits runway, forces reliance on external capital, and could slow trial timelines or program advancement if additional financing or partnering is delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin & revenue rebound
Sustained revenue rebound with ~97% gross margin indicates attractive unit economics on recognized revenue streams. For a clinical-stage biotech, high gross margins mean commercializable components or partnerships can scale efficiently, improving capital efficiency for ongoing R&D over the next several months.
Read all positive factors
HCW Biologics (HCWB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.36M
Dividend YieldN/A
Average Volume (3M)23.88M
Price to Earnings (P/E)<0.1
Beta (1Y)1.26
Revenue Growth356.16%
EPS Growth62.82%
CountryUS
Employees36
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.61
Shares Outstanding6,734,104
10 Day Avg. Volume67,354,671
30 Day Avg. Volume23,879,607
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.54
P/FCF Ratio-0.15
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit1.64
Enterprise Value/Ebitda-10.17
Forecast
1Y Price Target
$2.00Price Target Upside-49.87% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$900.00K
HCW Biologics Business Overview & Revenue Model
Company Description
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an ...
How the Company Makes Money
null...
HCW Biologics Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 54.23K | 2.57M | 2.84M | 6.72M | 0.00 |
| Gross Profit | 10.85K | 959.40K | 560.36K | 2.59M | 0.00 |
| EBITDA | -5.67M | -27.68M | -23.58M | -14.06M | -12.32M |
| Net Income | -7.96M | -30.02M | -24.99M | -14.90M | -12.86M |
Balance Sheet | |||||
| Total Assets | 24.52M | 30.24M | 28.51M | 46.81M | 53.51M |
| Cash, Cash Equivalents and Short-Term Investments | 1.95M | 4.67M | 3.60M | 32.06M | 36.71M |
| Total Debt | 6.81M | 13.69M | 6.30M | 6.41M | 0.00 |
| Total Liabilities | 21.76M | 37.01M | 15.05M | 9.38M | 2.32M |
| Stockholders Equity | 2.76M | -6.77M | 13.46M | 37.43M | 51.19M |
Cash Flow | |||||
| Free Cash Flow | -13.39M | -14.49M | -28.72M | -20.66M | -11.02M |
| Operating Cash Flow | -13.39M | -14.23M | -22.51M | -10.39M | -10.98M |
| Investing Cash Flow | 0.00 | -261.62K | 3.80M | 14.71M | -35.02M |
| Financing Cash Flow | 10.67M | 15.57M | -14.53K | 6.27M | 49.27M |
HCW Biologics Technical Analysis
Positive
3.99
Price Trends
0.56
Positive
0.76
Positive
2.12
Positive
Market Momentum
0.37
Negative
85.07
Negative
59.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HCWB, the sentiment is Positive. The current price of 3.99 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.56, and above the 200-day MA of 2.12, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 85.07 is Negative, neither overbought nor oversold. The STOCH value of 59.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HCWB.
HCW Biologics Risk Analysis
HCW Biologics disclosed 51 risk factors in its most recent earnings report. HCW Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
HCW Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $6.89M | -0.71 | -71.27% | ― | -55.97% | -198.81% | |
49 Neutral | $11.70M | -0.83 | -32.58% | ― | -100.00% | 13.00% | |
49 Neutral | $6.50M | -3.36 | -60.33% | ― | 23.52% | 48.34% | |
47 Neutral | $16.36M | 0.05 | -102.39% | ― | 356.16% | 62.82% | |
45 Neutral | $4.09M | -0.42 | -157.24% | ― | ― | 49.11% | |
42 Neutral | $3.27M | -0.15 | ― | ― | ― | 76.55% |
* Healthcare Sector Average
HCWB
HCW Biologics
2.58
-5.73
-68.95%
KPRX
Kiora Pharmaceuticals
2.68
-0.39
-12.70%
MTNB
Matinas BioPharma
0.67
-0.09
-11.97%
XBIO
Xenetic Biosciences
2.94
-0.10
-3.29%
ADXN
Addex Therapeutics
6.99
-1.41
-16.79%
CLDI
Calidi Biotherapeutics
0.19
-4.78
-96.16%
HCW Biologics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Raises $4M in Private Placement Financing
Positive
May 21, 2026
On May 21, 2026, HCW Biologics Inc. entered into a private securities purchase agreement with accredited healthcare-focused investors, issuing 2,846,975 units priced at $1.405 each for gross proceeds of about $4.0 million. Each unit comprised eith...
Private Placements and FinancingShareholder Meetings
HCW Biologics Adjourns Meeting, Seeks Approval for Warrants
Negative
Apr 30, 2026
HCW Biologics Inc., a clinical-stage biopharmaceutical company focused on fusion immunotherapeutics for chronic inflammation-related diseases, is working to advance a pipeline aimed at autoimmune conditions, cancer and senescence-associated disord...
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Prepares Investor Outreach Tied to Public Offering
Positive
Apr 30, 2026
On April 25, 2026, HCW Biologics agreed to enter a contingent consulting arrangement with I.R. Agency LLC to handle future marketing efforts aimed at communicating company information to the financial community, with $2.5 million in fees payable f...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
HCW Biologics Lowers Shareholder Meeting Quorum Requirement
Neutral
Apr 16, 2026
On April 15, 2026, HCW Biologics Inc.’s board approved an amendment to its Bylaws that will take effect on April 28, 2026, lowering the shareholder quorum requirement for conducting business at meetings. The new standard sets a quorum at 33 ...
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Secures $7M License Deal for HCW11-006
Positive
Mar 17, 2026
On March 17, 2026, HCW Biologics Inc., a U.S.-based commercial- and clinical-stage biopharmaceutical company developing fusion immunotherapies for autoimmune disease, cancer and senescence-associated dysplasia, reported it had received full paymen...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight
Positive
Mar 2, 2026
HCW Biologics Inc., a clinical-stage biopharmaceutical developer of novel immunotherapies targeting chronic inflammation and age-related, senescence-associated diseases, is advancing a pipeline led by HCW9302, an IL-2 fusion molecule in Phase 1 fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.